RecruitingNot ApplicableNCT06247189
ICOPE Program Feasibility in the Management of Myeloma Patients
Onco-ICOPE: ICOPE Program Feasibility in the Management of Myeloma Patients Over 70 Years
Sponsor
University Hospital, Toulouse
Enrollment
30 participants
Start Date
Dec 3, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
This project proposes to adapt monthly the existing ICOPE (Integrated Care for Older People) MONITOR program for elderly myeloma patients. This adaptation aims to detect earlier functional decline and prevent loss of autonomy.
Eligibility
Min Age: 70 Years
Inclusion Criteria10
- Male or female aged over 70 years,
- Patient with multiple myeloma
- WHO performance status 0-3,
- Patient eligible for first- or second-line treatment
- Patient willing to participate in ICOPE MONITOR program
- Patient or caregiver able to use digital tools of ICOPE MONITOR: application or chatbot (computer or tablet or smartphone)
- Patient with a life expectancy of more than 3 months,
- Patient or caregiver able to understand, read and speak French
- Person affiliated or benefiting from a social security.
- Free, informed and written consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research)
Exclusion Criteria5
- Patient in palliative care
- Patient participating in a study evaluating another frailty prevention program
- Patient unable to understand the study
- Patient under court protection, guardianship or curatorship,
- Patient refusal.
Interventions
OTHERICOPE Monitoring
At inclusion set up of the ICOPE monitor program on the patient's device and evaluation (all steps) of ICOPE Monitor program. Monthly, re-evaluation of the patient (Step 1 and others if necessary ) according to the ICOPE Monitor program
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06247189
Related Trials
Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma
NCT0617988873 locations
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
NCT0725851133 locations
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma
NCT068761421 location
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
NCT050924511 location
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
NCT02693535166 locations